CN114025765A - 巨环激酶抑制剂的多晶型 - Google Patents

巨环激酶抑制剂的多晶型 Download PDF

Info

Publication number
CN114025765A
CN114025765A CN202080044953.1A CN202080044953A CN114025765A CN 114025765 A CN114025765 A CN 114025765A CN 202080044953 A CN202080044953 A CN 202080044953A CN 114025765 A CN114025765 A CN 114025765A
Authority
CN
China
Prior art keywords
ret
crystalline polymorph
polymorph form
cancer
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044953.1A
Other languages
English (en)
Chinese (zh)
Inventor
邓维
E·W·罗杰斯
Y·卢
张晗
刘靖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tepu Pharmaceutical
Original Assignee
Tepu Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepu Pharmaceutical filed Critical Tepu Pharmaceutical
Publication of CN114025765A publication Critical patent/CN114025765A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080044953.1A 2019-06-19 2020-06-16 巨环激酶抑制剂的多晶型 Pending CN114025765A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US62/863,493 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US62/959,940 2020-01-11
US202063036102P 2020-06-08 2020-06-08
US63/036,102 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (1)

Publication Number Publication Date
CN114025765A true CN114025765A (zh) 2022-02-08

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044953.1A Pending CN114025765A (zh) 2019-06-19 2020-06-16 巨环激酶抑制剂的多晶型

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774A (zh) * 2021-06-25 2021-09-03 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026108A (zh) * 2015-07-06 2018-05-11 Tp生物医药公司 二芳基大环多晶型物
CN108026109A (zh) * 2015-07-21 2018-05-11 Tp生物医药公司 手性二芳基大环及其用途
US20180186813A1 (en) * 2015-07-02 2018-07-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CN110317213A (zh) * 2014-01-24 2019-10-11 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
CN111511746A (zh) * 2017-12-19 2020-08-07 特普医药公司 用于治疗疾病的巨环化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317213A (zh) * 2014-01-24 2019-10-11 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
US20180186813A1 (en) * 2015-07-02 2018-07-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CN108026108A (zh) * 2015-07-06 2018-05-11 Tp生物医药公司 二芳基大环多晶型物
CN113354653A (zh) * 2015-07-06 2021-09-07 特普医药公司 二芳基大环多晶型物及其制备方法
CN108026109A (zh) * 2015-07-21 2018-05-11 Tp生物医药公司 手性二芳基大环及其用途
CN111511746A (zh) * 2017-12-19 2020-08-07 特普医药公司 用于治疗疾病的巨环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHE NIE ET AL: "Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 2, pages 91 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774A (zh) * 2021-06-25 2021-09-03 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
WO2020257169A1 (en) 2020-12-24
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
IL288982A (en) 2022-02-01
PE20220135A1 (es) 2022-01-27
JP2022537385A (ja) 2022-08-25
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
TW202115090A (zh) 2021-04-16
EP3986413A4 (en) 2023-06-14
CO2022000405A2 (es) 2022-04-29
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP7212713B2 (ja) ジアリール大環状多形
AU2019267959A1 (en) ErbB receptor inhibitors
JP2019518776A (ja) Egfr阻害剤としてのアニリンピリミジン化合物の結晶
NO339357B1 (no) Fremgangsmåte for å fremstille poly(ADP-rlbose) polymerase Inhibitorer.
WO2012136099A1 (zh) 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
JP7789567B2 (ja) ピラゾロン縮合ピリミジン化合物、その製造方法及び使用
HU227569B1 (en) N-(3-ethynylpheyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate and pharmaceutical compositions containing the same
CN111868060B (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN115160309B (zh) Krasg12c突变蛋白杂环类抑制剂的制备及其应用
CN120092010A (zh) 多环类聚(adp核糖)聚合酶选择性抑制剂
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
CN114599656A (zh) 咪唑烷酮类化合物及其制备方法与应用
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
HK40059224B (en) Diaryl macrocycle polymorph and method for preparing the same
HK1254492B (en) Diaryl macrocycle polymorph

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220208

WD01 Invention patent application deemed withdrawn after publication